Progressive conduction disease late after adriamycin treatment of lymphoma, despite normalised ejection fraction

Progressive conduction disease late after adriamycin treatment of lymphoma, despite normalised ejection fraction

Adriamycin (doxorubicin) chemotherapy is known for its acute and late cardiotoxic complications1. In up to 2% of patients they manifest in the form of suppressed ventricular systolic function with its well known consequences, raised filling pressures and mitral regurgitation. Its potential direct ef...

Full description

Bibliographic Details
Main Authors: Catharina Lysell-Bergström, Bengt Johansson, Lars Widman, Owe Johnson, Stellan Mörner
Format: Article
Language:English
Published: Barcaray International 2014-01-01
Series:International Cardiovascular Forum Journal
Online Access:http://icfjournal.org/index.php/icfj/article/view/76/68
id doaj-ea553c9a0e2e49309981035228ccfc30
record_format Article
spelling doaj-ea553c9a0e2e49309981035228ccfc302020-11-25T01:38:19ZengBarcaray InternationalInternational Cardiovascular Forum Journal2410-26362409-34242014-01-0113160161Progressive conduction disease late after adriamycin treatment of lymphoma, despite normalised ejection fractionCatharina Lysell-Bergström0Bengt Johansson1Lars Widman2Owe Johnson3Stellan Mörner4Department of Public Health and Clinical Medicine & Heart Centre, Norrlands University Hospital, Umeå, SwedenDepartment of Public Health and Clinical Medicine & Heart Centre, Norrlands University Hospital, Umeå, SwedenDepartment of Public Health and Clinical Medicine & Heart Centre, Norrlands University Hospital, Umeå, SwedenDepartment of Public Health and Clinical Medicine & Heart Centre, Norrlands University Hospital, Umeå, SwedenDepartment of Public Health and Clinical Medicine & Heart Centre, Norrlands University Hospital, Umeå, SwedenAdriamycin (doxorubicin) chemotherapy is known for its acute and late cardiotoxic complications1. In up to 2% of patients they manifest in the form of suppressed ventricular systolic function with its well known consequences, raised filling pressures and mitral regurgitation. Its potential direct effect on conduction disturbances, however, has not been systematically described. We present a case of a patient who had severe heart failure following adriamycin lymphoma treatment who despite full recovery of systolic left ventricular (LV) function developed progressive conduction disease that required life saving cardiac pacing.http://icfjournal.org/index.php/icfj/article/view/76/68
collection DOAJ
language English
format Article
sources DOAJ
author Catharina Lysell-Bergström
Bengt Johansson
Lars Widman
Owe Johnson
Stellan Mörner
spellingShingle Catharina Lysell-Bergström
Bengt Johansson
Lars Widman
Owe Johnson
Stellan Mörner
Progressive conduction disease late after adriamycin treatment of lymphoma, despite normalised ejection fraction
International Cardiovascular Forum Journal
author_facet Catharina Lysell-Bergström
Bengt Johansson
Lars Widman
Owe Johnson
Stellan Mörner
author_sort Catharina Lysell-Bergström
title Progressive conduction disease late after adriamycin treatment of lymphoma, despite normalised ejection fraction
title_short Progressive conduction disease late after adriamycin treatment of lymphoma, despite normalised ejection fraction
title_full Progressive conduction disease late after adriamycin treatment of lymphoma, despite normalised ejection fraction
title_fullStr Progressive conduction disease late after adriamycin treatment of lymphoma, despite normalised ejection fraction
title_full_unstemmed Progressive conduction disease late after adriamycin treatment of lymphoma, despite normalised ejection fraction
title_sort progressive conduction disease late after adriamycin treatment of lymphoma, despite normalised ejection fraction
publisher Barcaray International
series International Cardiovascular Forum Journal
issn 2410-2636
2409-3424
publishDate 2014-01-01
description Adriamycin (doxorubicin) chemotherapy is known for its acute and late cardiotoxic complications1. In up to 2% of patients they manifest in the form of suppressed ventricular systolic function with its well known consequences, raised filling pressures and mitral regurgitation. Its potential direct effect on conduction disturbances, however, has not been systematically described. We present a case of a patient who had severe heart failure following adriamycin lymphoma treatment who despite full recovery of systolic left ventricular (LV) function developed progressive conduction disease that required life saving cardiac pacing.
url http://icfjournal.org/index.php/icfj/article/view/76/68
work_keys_str_mv AT catharinalysellbergstrom progressiveconductiondiseaselateafteradriamycintreatmentoflymphomadespitenormalisedejectionfraction
AT bengtjohansson progressiveconductiondiseaselateafteradriamycintreatmentoflymphomadespitenormalisedejectionfraction
AT larswidman progressiveconductiondiseaselateafteradriamycintreatmentoflymphomadespitenormalisedejectionfraction
AT owejohnson progressiveconductiondiseaselateafteradriamycintreatmentoflymphomadespitenormalisedejectionfraction
AT stellanmorner progressiveconductiondiseaselateafteradriamycintreatmentoflymphomadespitenormalisedejectionfraction
_version_ 1725054522718420992

Similar Items